Impact of executive dysfunction on naming ability in multiple sclerosis.

Rev Neurol (Paris)

Service neurologie, Zone C1, pôle neurosciences cliniques, centre de ressources et compétences SEP (CRC SEP), neurologie, université Nice Côte d'Azur, hôpital Pasteur 2, centre hospitalier universitaire de Nice, CHU Pasteur 2, 30, voie Romaine, 06001 Nice cedex 1, France.

Published: October 2019

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.neurol.2019.02.008DOI Listing

Publication Analysis

Top Keywords

impact executive
4
executive dysfunction
4
dysfunction naming
4
naming ability
4
ability multiple
4
multiple sclerosis
4
impact
1
dysfunction
1
naming
1
ability
1

Similar Publications

Background: Use of health applications (apps) to support healthy lifestyles has intensified. Different app features may support effectiveness, including gamification defined as the use of game elements in a non-game situation. Whether health apps with gamification can impact behaviour change and cardiometabolic risk factors remains unknown.

View Article and Find Full Text PDF

Background: Despite the immense impact of Long COVID on public health and those affected, its aetiology remains poorly understood. Findings suggest that psychological factors such as depression contribute to symptom persistence alongside pathophysiological mechanisms, but knowledge of their relative importance is limited. This study aimed to synthesise the current evidence on psychological factors potentially associated with Long COVID and condition-relevant outcomes like quality of life.

View Article and Find Full Text PDF

Work in many systems has shown large-scale changes in gene expression during aging. However, many studies employ just two, arbitrarily-chosen timepoints at which to measure expression, and can only observe an increase or a decrease in expression between "young" and "old" animals, failing to capture any dynamic, non-linear changes that occur throughout the aging process. We used RNA sequencing to measure expression in male head tissue at 15 timepoints through the lifespan of an inbred strain.

View Article and Find Full Text PDF

Apolipoprotein E4 (APOE4) is the strongest genetic risk factor for sporadic Alzheimer's disease (AD). Individuals with one copy of APOE4 exhibit greater amyloid-beta (Aβ) deposition compared to noncarriers, an effect that is even more pronounced in APOE4 homozygotes. Interestingly, APOE4 carriers not only show more AD pathology but also experience more rapid cognitive decline, particularly in episodic memory.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!